KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Comparison of drug-eluting bead transarterial chemoembolization combined with apatinib versus drug-eluting bead transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: a randomized, prospective, multicenter phase III trial.

Xuhua Duan, Hao Li, Donglin Kuang, Pengfei Chen, Mengfan Zhang, Tengfei Li, Dechao Jiao, Yanliang Li, Xiang He, Cheng Xing, Haibo Wang, Yaoxian Liu, Limin Xie, Shixi Zhang, Qiang Zhang, Peixin Zhu, Yongchuang Chang, Jichen Xie, Jianzhuang Ren, Xinwei Han

Signal Transduct Target Ther 9(1) 304

PMID39532849
PMCIDPMC11557926
DOI10.1038/s41392-024-02012-x
发表日期2024-11-12
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:图像复核确认至少一个 KM 面板含可见 No. at risk 表。
摘要

摘要

This randomized, prospective, multicenter (12 centers in China) phase III trial (Chinese Clinical Trial Registry #ChiCTR2000041170) compared drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with apatinib and DEB-TACE monotherapy for patients with unresectable hepatocellular carcinoma (uHCC). Progression-free survival (PFS) was the primary endpoint. Overall survival (OS), mRECIST-based objective response rates (ORR) and disease control rates (DCR), and treatment-related adverse events (TRAEs) were secondary endpoints. Totally 243 cases were randomized, with 122 and 121 in the DEB-TACE + apatinib and DEB-TACE groups, respectively. Cases administered DEB-TACE + apatinib displayed markedly improved median PFS (7.1 months [95%CI 6.6-8.3] vs. 5.2 months [95%CI 5.0-5.9]) and OS (23.3 months [95%CI 20.7-29.6] vs. 18.9 months [95%CI 17.9-20.1] compared with those treated with DEB-TACE (both p < 0.001). Additionally, patients administered DEB-TACE + apatinib had elevated ORR (56.6% vs. 38.8%) and DCR (89.3% vs. 80.2%) versus the DEB-TACE group (both p < 0.001). Majority of TRAEs were mild and manageable. Regarding DEB-TACE-related TRAEs, the rates of hepatic artery thinning and spasms were elevated during the second DEB-TACE in cases administered DEB-TACE + apatinib vs. DEB-TACE. The commonest apatinib-related TRAEs in the DEB-TACE + apatinib group included hypertension, hand-foot syndrome, fatigue, and diarrhea. In conclusion, DEB-TACE plus apatinib demonstrates superior PFS versus DEB-TACE monotherapy in uHCC cases, maintaining a favorable safety profile with similar occurrences of AEs.

KM 提取结果

1 个 Figure · 6 个 KM 面板

进入结果中心
KM Figure6 个面板

Fig. 2

Fig. 2 Kaplan-Meier curves for overall survival ( a , c , and e ) and progression-free survival ( b , d , and f ) estimation in both groups in all patients ( a , b ) and in cases with BCLC B ( c , d ), and BCLC C ( e , f ) lesions. Median (95%CI). DEB-TACE Drug-eluting bead transarterial chemoembolization, D + apatinib, DEB-TACE plus apatinib, BCLC Barcelona clinic liver cancer, P value for the log-rank test

A

overall survival

Fig. 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

progression-free survival

Fig. 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

overall survival

Fig. 2 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
D

progression-free survival

Fig. 2 · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
E

overall survival

Fig. 2 · Panel E

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel E 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
F

progression-free survival

Fig. 2 · Panel F

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel F 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Study flowchart. Abbreviations : DEB-TACE, Drug-eluting bead transarterial chemoembolization; D + apatinib, DEB-TACE plus apatinib; ITT, intention-to-treat population
非 KM Figure
Fig. 3Fig. 3 Images in a 59-year-old man with advanced hepatocellular carcinoma. a Hepatic angiography during the first TACE. b In the first DEB-TACE, CalliSpheres@ Beads with a diameter of 100-300 um loaded with 60 mg of doxorubicin were used to embolize the right hepatic artery, and the VL phenomenon occurred in the re-examination angiography (arrow). c PVA particles with a diameter of 350-560 μm were subsequently added for embolization until the VL phenomenon disappeared in the re-examination angiography. d Enhanced MRI at 4 weeks after the first DEB-TACE revealed partial contrast enhancement in the peripheral intrahepatic lesion, suggesting a partial response according to mRECIST criteria. Each small division on the scale bar represents 1 cm. e After 3 rounds of DEB-TACE plus apatinib, MR images at 6 months of follow-up show that the tumor had a complete response. Each small division on the scale bar represents 1 cm. f One-year follow-up MR images show that the tumor had a complete response. Each small division on the scale bar represents 1 cm
非 KM Figure